Clinical Research Directory
Browse clinical research sites, groups, and studies.
UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
Sponsor: Shanghai Life Science & Technology
Summary
A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation
Official title: Safety and Efficacy Evaluation of Umbilical Cord Mesenchymal Stem Cells Transcatheter Transplantation to Treat Left Ventricular Dysfunction After Acute Myocardial Infarction
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
0
Start Date
2024-12-01
Completion Date
2025-12-31
Last Updated
2026-05-11
Healthy Volunteers
No
Interventions
UC-MSC
0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU, at the concentration of 2x10(7) cells/ml.
Control Group
Routine treatment without catheter infusion
Locations (1)
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Shanghai, Shanghai Municipality, China